LIVE ACTIVITIES

Online offerings provide virtual, faculty-led presentations you can view from your own computer or smart device.

 

Mar
11
Wed
The Virtual Reality Room Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors
Mar 11 2020 @ 12:00 am – Mar 11 2021 @ 11:45 pm

The Virtual Reality Room Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors

VIEW ACTIVITY

 

Please note that this program was recorded before the indication for dupilumab was expanded on May 26, 2020.

Dupilumab is now indicated for patients 6 years of age or older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This approval is based on the results from pivotal phase III trials which have shown that children and adolescents treated with dupilumab experience significant improvements in overall disease severity, skin clearance, and itch.

FACULTY

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary and Critical Care Medicine
University of Wisconsin School of Medicine and Public Health
Madison, WI

PROGRAM OVERVIEW

This online activity is focused on the team involved in the management of patients with type 2 inflammation in atopic diseases.

TARGET AUDIENCE

This activity is intended for U.S.-based pulmonologists, allergists, immunologists, otolaryngologists, pediatric/adolescent dermatologists, and other primary health care professionals (physicians, physician assistants, nurse practitioners) involved in the management of patients with atopic diseases including asthma, CRSwNP, and AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the Th2 inflammatory pathways and cascades underlying the pathophysiology of atopic diseases including asthma, CRSwNP, and AD
  • Review the clinical profiles and mechanisms of action of interleukin inhibitors used for the treatment of atopic diseases including asthma, CRSwNP, and AD
  • Develop treatment plans for patients with atopic diseases including asthma, CRSwNP, and AD based on patient-specific factors relevant to clinical decision making

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with atopic diseases including asthma, CRSwNP, and AD.
CNE Credits: 1.5 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

William W. Busse, MD received consulting fees from Sanofi, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Novartis. He serves on the Speakers Bureau for Regeneron, received royalty from Elsevier, and served on the Data Safety Monitoring Board for Boston Scientific.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical and Scientific Services, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE
credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: March 11, 2020

EXPIRATION DATE: March 11, 2021

 

View Activity

 

Jun
11
Thu
AAAAI AD Virtual Symposium – Dr. Amy Paller and Dr. Lawrence Sher
A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Jun 11 2020 @ 8:00 am – Jun 11 2021 @ 5:00 pm

A Virtual Reality View:
New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

Lawrence D. Sher, MD, FAAP, FAAAAI, FACAAI, CPI (ACRP)
Medical Director
Palos Verdes Medical Group
Peninsula Research Associates
Rolling Hills Estates, CA

PROGRAM OVERVIEW

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other healthcare professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
  • Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
  • Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Amy S. Paller, MD, has nothing to disclose.

Lawrence D. Sher, MD, FAAP, FAAAAI, FACAAI, CPI (ACRP), is on the speakers’ bureau for Regeneron. Dr. Sher has contracted research for Regeneron, Sanofi, Glenmark, Pfizer, Leo, Aimmune, and AstraZeneca.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 11, 2020

EXPIRATION DATE: June 11, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

 

AAD AD Virtual Symposium – Dr. Amy Paller and Dr. Peter Lio
A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Jun 11 2020 @ 8:00 am – Jun 11 2021 @ 5:00 pm

A Virtual Reality View:
New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology/Associates of Chicago
Chicago, IL

PROGRAM OVERVIEW

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other healthcare professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
  • Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
  • Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Amy S. Paller, MD, has nothing to disclose.

Peter A. Lio, MD, has received grants as an investigator and/or honoraria for lecturing, and/or consulting fees from: Eli Lilly, UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, La Roche Posay/L’Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Burt’s Bees, and the National Eczema Association.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 11, 2020

EXPIRATION DATE: June 11, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

 

Oct
23
Fri
Infographic Virtual Preceptorship: Multidisciplinary Care of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Oct 23 2020 @ 4:39 am – Oct 23 2021 @ 5:39 am

Infographic Virtual Preceptorship: Multidisciplinary Care of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

View Activity

 

Program Toolkit

Download Your Complimentary Poster

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Professor Dermatology and Pediatrics
Northwestern Medicine Feinberg School of Medicine
Chicago, IL

PROGRAM OVERVIEW

This enduring activity will cover HCPs involved in the management of pediatric and adolescent patients with atopic dermatitis.

TARGET AUDIENCE

This activity is intended for dermatologists, pediatric dermatologists, pediatricians, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Develop treatment plans for the management of atopic dermatitis in pediatric and adolescent patients that incorporate guideline recommendations, evidence from clinical trials, and patient-specific factors
  • Identify patients who would benefit from treatment intensification based on disease severity, failure of prior therapy, and comorbid conditions
  • Incorporate strategies into clinical practice that encourage patient-centered and multidisciplinary care of atopic dermatitis

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 0.50 AMA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD.

Credits: 0.50 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.50 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Amy S. Paller, MD, served as consultant to Almirall, Amgen, Asana, Boehringer-Ingelheim, Castle Creek, Celgene, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Galderma, Lenus, Leo, Meda Corp., Meiji Seika, Novan, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and Sol Gel.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: October 23, 2020

EXPIRATION DATE: October 23, 2021

Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

Nov
4
Wed
Online Situation Room: Improving the Ability to Diagnose and Treat Atopic Dermatitis in Clinical Practice A part of the THRIVE – Atopic Dermatitis Initiative
Nov 4 2020 @ 5:42 am – Nov 4 2021 @ 6:42 am

Online Situation Room: Improving the Ability to Diagnose and Treat Atopic Dermatitis in Clinical Practice A part of the THRIVE – Atopic Dermatitis Initiative

View Activity

FACULTY


Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Chicago, IL

Jonathan Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Endowed Chair of Pediatrics
Director, World Allergy Organization Center of Excellence
Director of Center for Pediatric Eosinophilic Disease
Director, FARE Center of Excellence at The Children’s Hospital of Philadelphia
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

PROGRAM OVERVIEW

This “situation room” activity allows learners to practice making clinical decisions in the management of patients with moderate-to-severe atopic dermatitis. Learners will view simulated 3D interactions between patients and their physicians and use information from the patients’ electronic charts to decide the next best course of action. Topics covered in this activity include assessment of disease severity and quality of life, intensification of treatment, and recognizing adverse events.


TARGET AUDIENCE

This activity is intended for dermatologists, allergists/immunologists, and primary healthcare professionals (physicians, nurse practitioners, and physician assistants) involved in the management of patients with AD.


LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Describe the role of Type 2 cytokines in the pathophysiology of AD and other overlapping Type 2 diseases
  • Incorporate AD diagnostic and assessment tools as well as consideration of patient-specific factors in clinical evaluations of patients with AD
  • Discuss the safety and efficacy of existing and emerging AD treatments based on current research and clinical trial data
  • Review the comorbid conditions associated with AD, such as asthma and allergic conjunctivitis, and how to manage them in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
Credits: 1.0 ANCC Contact Hours


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Lio has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, DermVeda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron, Pfizer, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Exeltis, Therplex, Odeza LLC, L’Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees.

Dr. Spergel is a consultant for Regeneron- Sanofi, Novartis, DBV Technology, and Kaleo. Dr. Spergel has completed contracted research for Regeneron-Sanofi, and Novartis, and has received royalty from Uptodate.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.


The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: November 4, 2020

EXPIRATION DATE: November 4, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Med learning group will be glad to assist you with any special needs. Please contact Med Learning Group at any time at info@medlearninggroup.com.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

Jan
13
Wed
The Evolving Role of Systemic Therapies in the Management of Atopic Dermatitis: Key Principles in Patient Care and Education
Jan 13 2021 @ 12:00 am – Jan 13 2022 @ 6:21 am

The Evolving Role of Systemic Therapies in the Management of Atopic Dermatitis: Key Principles in Patient Care and Education

VIEW ACTIVITY

FACULTY

Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH
Professor of Dermatology
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

PROGRAM OVERVIEW

This online activity will review evidence-based approaches to the diagnosis and management of atopic dermatitis (AD), in addition to associated quality of life issues and adverse events associated with disease and treatment.

TARGET AUDIENCE

This activity is intended for pediatricians, dermatologists, pediatric dermatologists, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Apply evidence-based approaches to diagnose, assess, and manage moderate-to-severe atopic dermatitis in pediatric and adolescent patients
  • Assess the physical, psychosocial, and developmental impact of atopic dermatitis on patients’ quality of life when selecting therapy options and evaluating therapeutic outcomes
  • Recognize and manage the adverse events associated with systemic and topical therapies for the management of atopic dermatitis in pediatric and adolescent patients

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of pediatric and adolescent patients with atopic dermatitis.
Credits: 1.25 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Peter Lio, MD has received grants as an investigator and/or honoraria for lecturing, and/or consulting fees from: Eli Lilly, UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, La Roche Posay/L’Oreal, Pierre-Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs, Verrica, TopMD, Arbonne, Burt’s Bees, and the National Eczema Association.

Jonathan I. Silverberg, MD, PhD, MPH is consultant and/or advisory board member for Abbvie, Afyx, Arena, Asana, Bluefin, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi, and is on the speaker’s bureau for Sanofi-Regeneron.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
Chris Drury, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete the pre-and-post survey and evaluation.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: January 13, 2021

EXPIRATION DATE: January 13, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

 

Mar
16
Tue
The New Paradigm in the Management of Moderate-to-Severe Atopic Dermatitis: Improving Symptoms and Quality of Life with Systemic Therapies
Mar 16 @ 7:30 pm – 8:30 pm

The New Paradigm in the Management of Moderate-to-Severe Atopic Dermatitis: Improving Symptoms and Quality of Life with Systemic Therapies

REGISTER FOR LIVE VIRTUAL PROGRAM

Tuesday, March 16, 2021

7:30 PM – 8:30 PM ET

Please note this virtual program is 7:30PM Eastern, 6:30PM Central, 5:30PM Mountain and 4:30PM Pacific.

Program Features

• Interactive, case-based learning
• NEW 2D and 3D animations
• Create your own personalized poster

Faculty

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology/Associates of Chicago
Chicago, IL

Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health
University of Colorado School of Medicine
Denver, CO

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess disease severity in patients with AD and identify patients who require treatment intensification
  • Utilize guideline recommendations and clinical trial data to design treatment regimens that address the symptoms and quality of life of patients with AD
  • Incorporate shared decision-making into clinical practice to improve treatment adherence and patient outcomes

Target Audience

This activity is intended for dermatologists, pediatric dermatologists, and other healthcare professionals involved in the management of patients with atopic dermatitis.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with atopic dermatitis.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues that you believe would be interested in attending this free CME/CNE program.

 

 

REGISTER FOR LIVE VIRTUAL PROGRAM

Apr
16
Fri
Using Managed Care to Minimize the Burden of Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients
Apr 16 @ 6:30 pm – 7:30 pm

Using Managed Care to Minimize the Burden of Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients

REGISTER FOR LIVE VIRTUAL PROGRAM

Friday, April 16, 2021

6:30 PM– 7:30 PM ET

Please note this virtual program is 6:30PM Eastern, 5:30PM, Central, 4:30PM Mountain and 3:30PM Pacific.

Program Features

  • Animations – new 2D and 3D!
  • Interactive, case-based learning
  • Create your own personalized poster

Faculty

Peter A. Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, IL

Geoffrey C. Wall, PharmD, FCCP, BCPS
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Recognize patient-specific factors that influence the selection of therapies for the management of moderate-to-severe atopic dermatitis, including comorbidities, adherence barriers, disease severity, and quality-of-life issues
  • Evaluate clinical trial data on the efficacy and safety of systemic and topical treatments for the management of moderate-to-severe atopic dermatitis
  • Identify strategies to manage healthcare costs while improving quality of life for patients with atopic dermatitis
  • Develop treatment plans that apply evidence-based medication use strategies to enhance outcomes in patients with moderate-to-severe atopic dermatitis

Target Audience

This activity is intended for managed care pharmacists, physicians, and other healthcare professionals involved in the management of patients with moderate-to-severe atopic dermatitis.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with atopic dermatitis.

Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

CONTINUING PHARMACY EDUCATION CREDIT

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.

NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues that you believe would be interested in attending this free CME/CNE program.

 

 

REGISTER FOR LIVE VIRTUAL PROGRAM

GRAND ROUNDS: CLICK ON STATES TO SEE ACTIVITIES

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These CME activities are planned and produced in accordance with the ACCME Essentials.